Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Apr 03 2014 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 25 2014 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Feb 03 2014 Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Jan 13 2014 Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 06 2014 Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Dec 09 2013 2013 ASH 682-06 MDS Poster Dec 09 2013 Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML Nov 12 2013 Cyclacel Reports Third Quarter 2013 Financial Results Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting Nov 06 2013 Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens Oct 31 2013 Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference Sep 19 2013 Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer Aug 14 2013 Cyclacel Reports Second Quarter 2013 Financial Results Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis Aug 08 2013 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results Jul 05 2013 Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013 May 21 2013 Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering May 16 2013 Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering May 15 2013 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock May 13 2013 Cyclacel Reports First Quarter 2013 Financial Results May 10 2013 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results Apr 30 2013 Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None202320222021202020192018201720162015201420132012201120102009200820072006 Apr 03 2014 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 25 2014 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Feb 03 2014 Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Jan 13 2014 Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 06 2014 Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Dec 09 2013 2013 ASH 682-06 MDS Poster Dec 09 2013 Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML Nov 12 2013 Cyclacel Reports Third Quarter 2013 Financial Results Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting Nov 06 2013 Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens Oct 31 2013 Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference Sep 19 2013 Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer Aug 14 2013 Cyclacel Reports Second Quarter 2013 Financial Results Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis Aug 08 2013 Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results Jul 05 2013 Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013 May 21 2013 Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering May 16 2013 Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering May 15 2013 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock May 13 2013 Cyclacel Reports First Quarter 2013 Financial Results May 10 2013 Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results Apr 30 2013 Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting
Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens
Aug 12 2013 Cyclacel's Seliciclib to be Evaluated in Investigator-Initiated Clinical Study to Treat Rheumatoid Arthritis
